Exo Therapeutics Raises $78M in Series B Financing

Exo Therapeutics, Inc., a Cambridge, Mass.-based small molecule drug discovery and development company, closed a $78m Series B financing.

The round was led by new investor Nextech Invest with participation from BVF Partners, Samsara Biocapital, Morningside and Casdin Capital, and existing investors Newpath Partners, Novartis Venture Fund, CRV and 6 Dimensions Capital. As part of the financing, Thilo Schroeder, PhD, Partner at Nextech Invest, and Kanishka Pothula, Managing Director at BVF Partners, L.P., joined Exo’s Board of Directors.

The company intends to use the funds to advance therapeutic candidates in oncology and inflammation derived from its proprietary ExoSightTM platform towards proof-of-concept and into the clinic and expand its pursuit of new targets with the ExoSight platform.

Led by Michael Bruce, PhD, CEO, Exo Therapeutics is a small molecule drug discovery and development company with technology to address intractable pharmaceutical targets. By leveraging the company’s ExoSightTM platform, Exo is developing a deep pipeline of potent drug candidates that bind exosites, distal and unique binding pockets that have the potential to reprogram enzyme activity for precise and robust therapeutic effect.

FinSMEs

11/10/20210